1027979-11-8

Basic information

• Product Name: (αR)-4-methoxy-3-(3-methoxypropoxy)-α-(1-methylethyl)benzenepropanal
• Synonyms: (αR)-4-methoxy-3-(3-methoxypropoxy)-α-(1-methylethyl)benzenepropanal
• CAS NO: 1027979-11-8
• Molecular Weight: 294.391
• Mol File: 1027979-11-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (αR)-4-methoxy-3-(3-methoxypropoxy)-α-(1-methylethyl)benzenepropanal(CAS DataBase Reference)
• NIST Chemistry Reference: (αR)-4-methoxy-3-(3-methoxypropoxy)-α-(1-methylethyl)benzenepropanal(1027979-11-8)
• EPA Substance Registry System: (αR)-4-methoxy-3-(3-methoxypropoxy)-α-(1-methylethyl)benzenepropanal(1027979-11-8)

Safety Data

• Hazardous Substances Data: 1027979-11-8(Hazardous Substances Data)

Upstream product

• 172900-73-1 4-(bromomethyl)-1-methoxy-2-(3-methoxypropoxy)-benzene 
• 145589-03-3 (R)-4-benzyl-3-(3-methylbutyryl)oxazolidin-2-one 
• 325154-22-1 2-isopropyl-3-{2-[3-methoxy(propyloxy)]-4-methoxyphenyl}propionic acid 
• 1351987-18-2 butyl-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutanoate 
• 325154-21-0 ethyl 2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutanoate 
• 1351987-21-7 methyl-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutanoate 
• 1351987-20-6 C₂₁H₃₂O₅ 
• 1351987-19-3 C₂₁H₃₄O₆ 
• 109-19-3 butyl isovalerate 
• 172900-75-3 4-methoxy-3-(3-methoxypropoxy)benzaldehyde 
• 172900-71-9 (R)-3-[4-methoxy-3-(3-methoxypropoxy)phenyl]-2-(1-methylethyl)propanoic acid 
• 172900-70-8 (R)-2-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methylbutanol 
• 1256556-40-7 (1S,3R,R)-3-(1-(4-methoxy-3-(3-methoxypropoxy)phenyl)-3-methylbutan-2-yl)-1-phenyl-2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazine 
• 1073553-77-1 2-isopropyl-3-[4-methoxy-3-(3-methoxypropoxy)phenyl]propenal 

Downstream Products

• 172900-70-8 (R)-2-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methylbutanol 
• 866030-35-5 tert-butyl {(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl}carbamate 
• 900811-38-3 (R)--4-(2-(iodomethyl)--3--methylbutyl)--1--methoxy-2--(3--methoxypropoxy)benzene 
• 1236549-00-0 {(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxo-furanidin-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid benzyl ester 
• 1351987-22-8 C₁₈H₃₀O₆S 
• 1351987-30-8 (5S)-ethyl-5-(((S)-4-benzyloxazolidin-2-on-3-yl)carbonyl)-2-((R)-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutyl)-6-methyl-3-oxoheptanoate 
• 1351987-31-9 (S,E)-ethyl-3-acetoxy-5-(((S)-4-benzyloxazolidin-2-on-3-yl) carbonyl)-2-((S)-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutyl)-6-methylhept-2-enoate 
• 1351987-33-1 (5S)-6-benzyl-1-tert-butyl-5-isopropyl-2-((R)-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutyl)-3-oxohexanedioate 
• 1351987-34-2 (S,E)-6-benzyl-1-tert-butyl-3-acetoxy-5-isopropyl-2-((S)-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutyl)hex-2-enedioate 
• 1351987-35-3 (S,E)-3-acetoxy-5-((benzyloxy)carbonyl)-2-((S)-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutyl)-6-methylhept-2-enoicacid 
• 1351987-36-4 (2S,3S,5S)-3-acetoxy-5-(benzyloxycarbonyl)-2-((R)-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutyl)-6-methylheptanoic acid 
• 1351987-37-5 (2S,4S,5S,7S)-benzyl-4-acetoxy-5-(benzyloxycarbonylamino)-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanoate 
• 1351987-29-5 (S)-ethyl 5-(((S)-4-benzyl-2-oxooxazolidin-3-yl)-carbonyl)-2-((R)-2-(4-methoxy-3-(3-methoxypropoxy)-benzyl)-3-methylbutylidene)-6-methyl-3-oxoheptanoate 
• 900811-48-5 3(S)-isopropyl-5(S)-{1(S)-amino-3(S)-isopropyl-4-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-butyl}-tetrahydrofuran-2-one 

Relevant articles and documents

A stereoselective catalytic nitroaldol reaction as the key step in a strategy for the synthesis of the renin inhibitor aliskiren

Aliskiren is the first-in-class orally active direct renin inhibitor. It was approved in 2007 for the treatment of hypertension. We have designed a new strategy for the convergent synthesis of aliskiren that involves a catalytic stereoselective nitroaldol reaction as the key step. A new enantiopure nitroalkane (synthon A1), prepared in only three steps from a commercially available enantiopure 2-(arylmethyl)-3-methyl butanol derivative, was successfully used in a copper-catalysed Henry reaction to give a nitrolactone intermediate in which the correct configuration for the final product was established at all four stereocentres. Nitro-group reduction, Boc-protection of the resulting amine, aminolysis of the lactone with 3-amino-2,2-dimethylpropionamide, and finally Boc-deprotection led to the enantiopure renin inhibitor aliskiren.

PROCESS FOR PREPARING 8-ARYLOCTANOIC ACIDS

The present invention relates to a process for preparing aliskiren and, more particularly, to an improved method for synthesizing a β-amino alcohol or a lactone analog thereof via the corresponding nitro derivatives of formula (Ia) or (Ib) these intermediates being used in the preparation of aliskiren.

PROCESS FOR PRODUCING ALISKIREN

A new route of synthesis of the compound Aliskiren of formula (I), used in the treatment of hypertension, is described.